Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Myelomonocytic Leukemia: early-phase trial registry
30 of 74 indexed Chronic Myelomonocytic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #183 of 28,707 conditions by registered trial count.
74 US clinical trials · 30 currently recruiting · #183 of 28,707 conditions by registered trial count
Chronic Myelomonocytic Leukemia: 74 US clinical trials tracked, 30 recruiting.
Chronic Myelomonocytic Leukemia is the subject of 74 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 70 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 15 of these trials.
Enrollment posture brief
Registry condition chronic-myelomonocytic-leukemia
OPEN 30 | RECR 41% | LATE 3 | EARLY 70 | RANK #183 | SPON 15
Volume-matched condition peers
Nearest open-share peer: Pain, Acute (41% recruiting · 32 trials)
Chronic Myelomonocytic Leukemia lists 30 open slots (41% of 74 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Myelomonocytic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Myelomonocytic Leukemia recruits in line with its size-band peers.
30 of 74 indexed trials (40.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chronic Myelomonocytic Leukemia research.
M.D. Anderson Cancer Center accounts for 15 of 74 trials (20.3%). 37 distinct sponsors appear on at least one study for this condition label.
-
Most Chronic Myelomonocytic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 52 among the 74 trials that report a genuine target (sentinel values excluded). 57 of those (77%) plan for fewer than 100 participants.
-
Chronic Myelomonocytic Leukemia research is mostly interventional.
73 interventional and 1 observational studies make up this index (98.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
74 total, page 2 of 2
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
NCT05364762
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT00002798
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group
NCT01305200
Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
NCT02397720
Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
NCT00067808
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
Fred Hutchinson Cancer Center
NCT00027820
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)
Stemline Therapeutics
NCT02268253
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
National Cancer Institute (NCI)
NCT00084916
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT00299156
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT00005845
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
National Cancer Institute (NCI)
NCT00351975
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Albert Einstein College of Medicine
NCT01772420
Ascorbic Acid Levels in MDS, AML, and CMML Patients
Van Andel Research Institute
NCT03526666
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01812252
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
University of Washington
NCT01101880
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT01083706
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT00052520
Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer
National Cancer Institute (NCI)
NCT00012376
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
Dana-Farber Cancer Institute
NCT00136409
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
NCT03515512
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
Stanford University
NCT03734601
Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome
Brian Jonas
NCT02553941
A Study of E7820 in People With Bone Marrow (Myeloid) Cancers
Memorial Sloan Kettering Cancer Center
NCT05024994
A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
University of Utah
NCT01350947
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 31 |
| Phase 2 | 39 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Myelomonocytic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Myelomonocytic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Myelomonocytic Leukemia page
74 registered trials, 30 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 30 Chronic Myelomonocytic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Chronic Myelomonocytic Leukemia trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Myelomonocytic Leukemia condition card totals 74 registered trials; most-linked intervention Azacitidine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.